Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
批准号:
10572816
负责人:
Danni Li
金额:
$23.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2023-05-31
关键词:
Administrative SupplementAerobic ExerciseAlzheimer&aposs DiseaseArizonaAwardBiological MarkersBloodCOVID-19CognitionCognitiveCollectionData CollectionDisease ProgressionEducational InterventionElderlyEnrollmentEpidemicExerciseFundingGlial Fibrillary Acidic ProteinGoalsImpaired cognitionInterventionLeftMinnesotaParentsParticipantPhasePlasmaPrevention strategyPublic HealthResearchSample SizeScheduleSiteSourceSurrogate EndpointTimeLineTreatment ProtocolsUniversitiesamnestic mild cognitive impairmentcognitive trainingexercise interventionexercise trainingintervention effectmagnetic resonance imaging biomarkerneuroinflammationpreservationpreventpublic health relevancerecruitresponsesulfated glycoprotein 2treatment responsetreatment strategy
中文摘要
项目摘要
母体R 01的目的是研究血液神经病理学和神经营养学生物标志物,
遗忘型轻度认知功能障碍老年人对3种干预措施的治疗反应的替代终点
损害(aMCI,AD的前驱阶段):有氧运动;认知训练;以及有氧运动和认知训练的组合。
认知训练(ACT)。这种补充的第一个目标是提供财政来源,因此,
母公司R 01有足够的资金来利用ACT试验修订后的入组时间轴,
在原合同范围内保留母公司R 01的总体影响。父R 01构建在
ACT试验,一项多中心II期RCT,检查6个月ACT干预对
认知和MRI生物标志物(n=128)。ACT试验于2020年3月因新型冠状病毒肺炎暂停入组。
19关闭罗切斯特大学(UR)和明尼苏达大学(UMN)的研究基地。我们
无法在2020年招募ACT试验的参与者。ACT试验已重新配置其研究时间轴,
考虑到由于招募暂停而损失的招募期。它还在亚利桑那州增加了第三个研究地点
州立大学(ASU)招聘。它将招募期延长至2022年8月31日,并以硬-
停止招募截止日期为2022年9月30日。所有数据收集将于2024年2月至3月结束。
然而,母公司R 01将于2022年5月31日结束,并且将没有足够的资金来利用
ACT试验修订后的入组时间轴。因此,我们需要这项行政补充,
招募和数据收集期,以最大限度地扩大样本量并完成母公司的范围
R01。该补充剂的第二个目标是通过研究血液,
神经炎症生物标志物作为aMCI中对3种干预措施的治疗应答的替代终点。
神经炎症调节AD的疾病进展。此外,最近的证据表明,
通过血浆聚集素调节神经炎症。此外,血胶质细胞酸性蛋白(GFAP)
已经成为神经炎症的生物标志物。这一证据表明,血液神经炎症
生物标志物如血浆GFAP和clusterin可以作为干预运动的替代终点-
相关的治疗反应。该添加在母产品R 01的范围内。第一个目标的具体目标
目标是:(1).在计划于2022年8月31日进行的ACT试验后继续招募受试者,或
2022年9月30日,如果到2022年8月31日仍未达到入组目标;(2)。完成所有血液采集
到2024年3月。第二个目标的具体目标是:(3)。确定干预措施对血液的影响
aMCI中的神经炎症生物标志物;(4).评价血液神经炎症生物标志物作为替代物
终点预测aMCI干预的认知反应。
英文摘要
Project Summary
The objective of the parent R01 is to investigate blood neuropathological and neurotrophic biomarkers as
surrogate endpoints for treatment responses to 3 interventions in older adults with amnestic mild cognitive
impairment (aMCI, a prodromal stage of AD): aerobic exercise; cognitive training; and combined aerobic
exercise and cognitive training (ACT). The first goal of this supplement is to provide financial sources, so the
parent R01 has sufficient funding to take advantage of the revised enrollment timeline of the ACT Trial to
preserve the parent R01's overall impact within the original scope of the award. The parent R01 is built on the
ACT trial, a multi-site Phase II RCT that examines the synergistic effects of a 6-month ACT intervention on
cognition and MRI biomarkers (n=128). The ACT Trial paused its enrollment in March 2020 due to the Covid-
19 shutdown of research at the University of Rochester (UR) and the University of Minnesota (UMN) sites. We
could not enroll the participants in the ACT Trial in 2020. The ACT Trial has re-configured its study timeline to
account for the lost recruitment period due to enrollment pause. It also added a 3rd study site at the Arizona
State University (ASU) to recruit. It extended its recruitment period to the end of August 31, 2022, with a hard-
stop recruitment ending date of September 30, 2022. All data collections will end on Feb-March 2024.
However, the parent R01 will end on May 31, 2022, and will not have sufficient funding left to take advantage
of the revised enrollment timeline of the ACT Trial. Hence, we need this administrative supplement to extend
the recruitment and data collection period to maximize sample size and accomplish the scope of the parent
R01. The second goal of this supplement is to increase the parent R01's impact by investigating blood
neuroinflammation biomarkers as surrogate endpoints for treatment responses to 3 interventions in aMCI.
Neuroinflammation modulates disease progression of AD. In addition, recent evidence suggests that exercise
modulate neuroinflammation through plasma clusterin. Furthermore, blood glial fibrillary acidic protein (GFAP)
has emerged as a biomarker for neuroinflammation. This evidence suggests that blood neuroinflammation
biomarkers such as plasma GFAP and clusterin could serve as surrogate endpoints for intervention exercise-
related treatment responses. This addition is within the scope of the parent R01. The specific aims for the first
goal are: (1). Continue enrolling participants following the ACT Trial scheduled to August 31, 2022, or
September 30, 2022, if not meeting the enrollment goal by August 31, 2022; (2). Complete all blood collections
by March 2024. The specific aims for the second goal are: (3). Determine the effects of interventions on blood
neuroinflammation biomarkers in aMCI; (4). Evaluate blood neuroinflammation biomarkers as surrogate
endpoints for predicting cognitive responses to interventions in aMCI.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3233/adr-210302
发表时间:
2021
期刊:
Journal of Alzheimer's disease reports
影响因子:
--
作者:
[Li D, Zhang L, Nelson NW, Mielke MM, Yu F]
通讯作者:
Yu F
DOI:
10.1002/pmic.202000224
发表时间:
2021-03
期刊:
Proteomics
影响因子:
3.4
作者:
[]
通讯作者:
Identification of plasma lipoprotein proteins and lipids as biomarkers of innate-immunity and vascular contributions to Alzheimer's disease and Alzheimer's disease-related dementias in older adults
-
批准号:10660037
-
项目类别:
-
资助金额:$223.25万
-
财政年份:2023
-
负责人:Danni Li
-
依托单位:
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
-
批准号:10190758
-
项目类别:
-
资助金额:$48.02万
-
财政年份:2018
-
负责人:Danni Li
-
依托单位:
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
-
批准号:9752399
-
项目类别:
-
资助金额:$49.61万
-
财政年份:2018
-
负责人:Danni Li
-
依托单位:
海外基金